User login
Avoiding Diabetes in Patients With Hepatitis C
Epidemiologic data suggest that patients with chronic hepatitis C virus (HCV) infection have an increased risk for insulin resistance—and for overt diabetes.1,2 Specifically, Serfaty and Capteau have reported evidence for “a triangular interaction” between steatosis, inflammatory processes, and insulin resistance.1
Averting these metabolic risks is essential for several reasons: Most importantly, their development is associated with increased liver inflammation and progression to fibrosis and cirrhosis, as well as impaired response to antiviral medications.3,4 Additionally, type 2 diabetes in patients with chronic HCV has been associated with a 1.7-fold increased risk for hepatocellular carcinoma (HCC) and other malignancies.5,6
Though never directly linked with the metabolic syndrome, HCV has been associated with impaired insulin signaling and insulin resistance, in addition to hypocholesterolemia and steatosis. Lonardo et al went so far as to mark this constellation of effects as “a distinct HCV-associated dysmetabolic syndrome.” 4
The dysmetabolic syndrome places affected patients at increased risk for cardiovascular disease, according to Rzouq et al. Statins, they report, are safe and effective in patients with chronic HCV and appear to confer anti-HCV proliferative benefits, making them a potentially “life-saving therapy.”7
Because insulin resistance in the hepatic and peripheral tissues is at the very least “an obvious and significantly detrimental pathophysiologic feature of HCV infection,” Kawaguchi and Mazuta suggest that patients with chronic HCV be encouraged to follow the same dietary and lifestyle recommendations made to those with diabetes, obesity, and metabolic syndrome.2 Maintaining a healthy body weight and following a reasonable regimen of diet and exercise help protect the liver in HCV-infected patients, whereas overweight and obesity, high cholesterol levels, and fatty liver are associated with accelerated liver damage.3
Continue for another component of diabetes risk reduction >>
Another component of diabetes risk reduction in patients with HCV is controlling hypertension.8 Of note, treatment with angiotensin-blocking agents has been associated with reduced liver fibrosis in HCV patients, compared with those receiving no antihypertensives or diuretics, vasodilators, or calcium channel antagonists.8,9
Patients with HCV who do develop diabetes are advised against using insulin or a sulfonylurea (ie, glipizide, glimepiride, glyburide).2 Metformin is considered a safer option, and its use has been linked to a reduced risk for HCC.2,10 Diabetic patients with HCV can also reduce their risk for HCC by maintaining an A1C level below 7.0%, according to Arase et al.5
REFERENCES
1. Serfaty L, Capteau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29(suppl 2):13-25.
2. Kawaguchi Y, Mazuta T. Interaction between hepatitis C virus and metabolic factors. World J Gasterentol. 2014;20(11):2888-2901.
3. US Department of Veterans Affairs. Viral hepatitis: diet and nutrition. http://www.hepatitis.va.gov/patient/daily/diet/single-page.asp. Accessed May 26, 2015.
4. Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med. 2008;3(2):99-108.
5. Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57(3):964-973.
6. Takahashi H, Mizuta T, Eguchi Y, et al. Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol. 2011;46(6):790-798.
7. Rzouq F, Alahdab F, Olyaee M. Statins and hepatitis C virus infection: an old therapy with new scope. Am J Med Sci. 2014;348(5):426-430.
8. Arase Y, Suzuki F, Suzuki Y, et al. Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol. 2009;81(9):1584-1590.
9. Corey KE, Shah N, Misdraji J, et al. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009; 29(5):748-753.
10. Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother. 2013;47(10):1348-1352.
Epidemiologic data suggest that patients with chronic hepatitis C virus (HCV) infection have an increased risk for insulin resistance—and for overt diabetes.1,2 Specifically, Serfaty and Capteau have reported evidence for “a triangular interaction” between steatosis, inflammatory processes, and insulin resistance.1
Averting these metabolic risks is essential for several reasons: Most importantly, their development is associated with increased liver inflammation and progression to fibrosis and cirrhosis, as well as impaired response to antiviral medications.3,4 Additionally, type 2 diabetes in patients with chronic HCV has been associated with a 1.7-fold increased risk for hepatocellular carcinoma (HCC) and other malignancies.5,6
Though never directly linked with the metabolic syndrome, HCV has been associated with impaired insulin signaling and insulin resistance, in addition to hypocholesterolemia and steatosis. Lonardo et al went so far as to mark this constellation of effects as “a distinct HCV-associated dysmetabolic syndrome.” 4
The dysmetabolic syndrome places affected patients at increased risk for cardiovascular disease, according to Rzouq et al. Statins, they report, are safe and effective in patients with chronic HCV and appear to confer anti-HCV proliferative benefits, making them a potentially “life-saving therapy.”7
Because insulin resistance in the hepatic and peripheral tissues is at the very least “an obvious and significantly detrimental pathophysiologic feature of HCV infection,” Kawaguchi and Mazuta suggest that patients with chronic HCV be encouraged to follow the same dietary and lifestyle recommendations made to those with diabetes, obesity, and metabolic syndrome.2 Maintaining a healthy body weight and following a reasonable regimen of diet and exercise help protect the liver in HCV-infected patients, whereas overweight and obesity, high cholesterol levels, and fatty liver are associated with accelerated liver damage.3
Continue for another component of diabetes risk reduction >>
Another component of diabetes risk reduction in patients with HCV is controlling hypertension.8 Of note, treatment with angiotensin-blocking agents has been associated with reduced liver fibrosis in HCV patients, compared with those receiving no antihypertensives or diuretics, vasodilators, or calcium channel antagonists.8,9
Patients with HCV who do develop diabetes are advised against using insulin or a sulfonylurea (ie, glipizide, glimepiride, glyburide).2 Metformin is considered a safer option, and its use has been linked to a reduced risk for HCC.2,10 Diabetic patients with HCV can also reduce their risk for HCC by maintaining an A1C level below 7.0%, according to Arase et al.5
REFERENCES
1. Serfaty L, Capteau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29(suppl 2):13-25.
2. Kawaguchi Y, Mazuta T. Interaction between hepatitis C virus and metabolic factors. World J Gasterentol. 2014;20(11):2888-2901.
3. US Department of Veterans Affairs. Viral hepatitis: diet and nutrition. http://www.hepatitis.va.gov/patient/daily/diet/single-page.asp. Accessed May 26, 2015.
4. Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med. 2008;3(2):99-108.
5. Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57(3):964-973.
6. Takahashi H, Mizuta T, Eguchi Y, et al. Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol. 2011;46(6):790-798.
7. Rzouq F, Alahdab F, Olyaee M. Statins and hepatitis C virus infection: an old therapy with new scope. Am J Med Sci. 2014;348(5):426-430.
8. Arase Y, Suzuki F, Suzuki Y, et al. Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol. 2009;81(9):1584-1590.
9. Corey KE, Shah N, Misdraji J, et al. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009; 29(5):748-753.
10. Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother. 2013;47(10):1348-1352.
Epidemiologic data suggest that patients with chronic hepatitis C virus (HCV) infection have an increased risk for insulin resistance—and for overt diabetes.1,2 Specifically, Serfaty and Capteau have reported evidence for “a triangular interaction” between steatosis, inflammatory processes, and insulin resistance.1
Averting these metabolic risks is essential for several reasons: Most importantly, their development is associated with increased liver inflammation and progression to fibrosis and cirrhosis, as well as impaired response to antiviral medications.3,4 Additionally, type 2 diabetes in patients with chronic HCV has been associated with a 1.7-fold increased risk for hepatocellular carcinoma (HCC) and other malignancies.5,6
Though never directly linked with the metabolic syndrome, HCV has been associated with impaired insulin signaling and insulin resistance, in addition to hypocholesterolemia and steatosis. Lonardo et al went so far as to mark this constellation of effects as “a distinct HCV-associated dysmetabolic syndrome.” 4
The dysmetabolic syndrome places affected patients at increased risk for cardiovascular disease, according to Rzouq et al. Statins, they report, are safe and effective in patients with chronic HCV and appear to confer anti-HCV proliferative benefits, making them a potentially “life-saving therapy.”7
Because insulin resistance in the hepatic and peripheral tissues is at the very least “an obvious and significantly detrimental pathophysiologic feature of HCV infection,” Kawaguchi and Mazuta suggest that patients with chronic HCV be encouraged to follow the same dietary and lifestyle recommendations made to those with diabetes, obesity, and metabolic syndrome.2 Maintaining a healthy body weight and following a reasonable regimen of diet and exercise help protect the liver in HCV-infected patients, whereas overweight and obesity, high cholesterol levels, and fatty liver are associated with accelerated liver damage.3
Continue for another component of diabetes risk reduction >>
Another component of diabetes risk reduction in patients with HCV is controlling hypertension.8 Of note, treatment with angiotensin-blocking agents has been associated with reduced liver fibrosis in HCV patients, compared with those receiving no antihypertensives or diuretics, vasodilators, or calcium channel antagonists.8,9
Patients with HCV who do develop diabetes are advised against using insulin or a sulfonylurea (ie, glipizide, glimepiride, glyburide).2 Metformin is considered a safer option, and its use has been linked to a reduced risk for HCC.2,10 Diabetic patients with HCV can also reduce their risk for HCC by maintaining an A1C level below 7.0%, according to Arase et al.5
REFERENCES
1. Serfaty L, Capteau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29(suppl 2):13-25.
2. Kawaguchi Y, Mazuta T. Interaction between hepatitis C virus and metabolic factors. World J Gasterentol. 2014;20(11):2888-2901.
3. US Department of Veterans Affairs. Viral hepatitis: diet and nutrition. http://www.hepatitis.va.gov/patient/daily/diet/single-page.asp. Accessed May 26, 2015.
4. Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med. 2008;3(2):99-108.
5. Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57(3):964-973.
6. Takahashi H, Mizuta T, Eguchi Y, et al. Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol. 2011;46(6):790-798.
7. Rzouq F, Alahdab F, Olyaee M. Statins and hepatitis C virus infection: an old therapy with new scope. Am J Med Sci. 2014;348(5):426-430.
8. Arase Y, Suzuki F, Suzuki Y, et al. Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol. 2009;81(9):1584-1590.
9. Corey KE, Shah N, Misdraji J, et al. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009; 29(5):748-753.
10. Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother. 2013;47(10):1348-1352.
A Closer Look at Mother-to-Child HCV Transmission
Hepatitis C virus (HCV) infection is reported in 0.05% to 0.36% of children in developed nations.1 Since improved screening of donor blood and blood products began in the 1990s, vertical transmission has become the primary cause of HCV infection in children.1-5 As many as 4,000 new cases of pediatric HCV infection may develop each year in the United States.6
At present, no clear interventions exist to prevent mother-to-child transmission (MTCT) of HCV.4,7 No HCV vaccine is yet available, and most current antiviral therapies are not considered safe for pregnant patients: ribavirin and interferon α, for example, are in pregnancy categories X and C, respectively.3,7 (See “Safer HCV Treatment Options in Pregnancy?”8,9) Some might argue that HCV infection is reported in only 1% to 2% of pregnant women in industrialized countries7 and that the rate of MTCT is low at 2% to 10%.3-5 Nevertheless, researchers maintain that HCV during pregnancy is a “neglected condition” and call for substantial improvements in public health response to affected patients.3,4 Awareness of risk factors for MTCT is essential.
Vertical transmission is believed to be limited to women with detectable viral load,3,4,10 and the risk grows with increasing maternal viremia (ie, HCV RNA > 105 copies/mL1). Risk for MTCT is heightened in women who are coinfected with HIV,3,11 with one systematic review showing a 10.8% vertical transmission risk among coinfected women, versus 5.8% among those with HCV infection alone.2 Transmission risk is increased in mothers with a history of IV drug use or a sexual partner infected with HCV.10 Perinatal procedures that expose the infant to HCV-infected maternal blood (eg, episiotomy, internal fetal monitoring) also elevate MTCT risk.3,7,1011
The recently approved regimen of sofosbuvir/ledipasvir [Harvoni®] has a pregnancy category of B, based on animal studies alone; its manufacturer recommends use of this regimen in pregnant patients only if its potential benefits exceed the potential risk to the fetus.8 Similarly, a pregnancy category of B (again, based only on animal studies) has been assigned to the combination of ombitasvir/paritaprevir/ritonavir with dasabuvir [Viekira Pak™], and its use during pregnancy is recommended “only if clearly needed”; additionally, its coadministration with ribavirin is absolutely contraindicated.9
In an effort to identify strategies to reduce vertical transmission of HCV, researchers for the US Preventive Services Task Force (USPSTF)6 performed a review of studies on the impact of mode of delivery, breastfeeding practices, and other factors on MTCT. No difference in HCV transmission was found in vaginal vs cesarean deliveries; however, in one good-quality study, a higher MTCT rate was found among cases involving prolonged duration of ruptured membranes (> 6 h before delivery).
Continue for association between breastfeeding and HCV >>
The USPSTF researchers found no association between breastfeeding and HCV transmission,6 although the CDC recommends against the practice in HCV-infected women whose nipples are cracked or bleeding.5 Of note, both breastfeeding and cesarean delivery are associated with increased transmission risk among HCV/HIV coinfected women.7 HCV genotype is reported to have little impact on MTCT.1,10
Until the development of an effective HCV vaccine and safe, effective HCV treatment for pregnant patients,1,3 strategies to interrupt MTCT represent our best hope to protect children against HCV infection.
REFERENCES
1. Yeung CY, Lee HC, Chan WT, et al. Vertical transmission of hepatitis C virus: current knowledge and perspectives. World J Hepatol. 2014;6(9):643-651.
2. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59(6):765-773.
3. Prasad MR, Honegger JR. Hepatitis C virus in pregnancy. Am J Perinatol. 2013;30(2):149-159.
4. Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period: are they opportunities for treatment? J Viral Hepat. 2011;18(4):229-236.
5. CDC. Hepatitis C FAQs for health professionals. www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed February 9, 2015.
6. Cottrell EB, Chou R, Wasson N, et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2013;158(2):109-113.
7. Tosone G, Maraolo AE, Mascolo S, et al. Vertical hepatitis C virus transmission: main questions and answers. World J Hepatol. 2014;6(8):538-548.
8. Harvoni®: highlights of prescribing information. www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed February 15, 2015.
9. Viekira Pak™: highlights of prescribing information. www.rxabbvie.com/pdf/viekirapak_pi.pdf. Accessed February 15, 2015.
10. Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. J Med Virol. 2009;81(5):8836-843.
11. Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192:1880-1889.
Hepatitis C virus (HCV) infection is reported in 0.05% to 0.36% of children in developed nations.1 Since improved screening of donor blood and blood products began in the 1990s, vertical transmission has become the primary cause of HCV infection in children.1-5 As many as 4,000 new cases of pediatric HCV infection may develop each year in the United States.6
At present, no clear interventions exist to prevent mother-to-child transmission (MTCT) of HCV.4,7 No HCV vaccine is yet available, and most current antiviral therapies are not considered safe for pregnant patients: ribavirin and interferon α, for example, are in pregnancy categories X and C, respectively.3,7 (See “Safer HCV Treatment Options in Pregnancy?”8,9) Some might argue that HCV infection is reported in only 1% to 2% of pregnant women in industrialized countries7 and that the rate of MTCT is low at 2% to 10%.3-5 Nevertheless, researchers maintain that HCV during pregnancy is a “neglected condition” and call for substantial improvements in public health response to affected patients.3,4 Awareness of risk factors for MTCT is essential.
Vertical transmission is believed to be limited to women with detectable viral load,3,4,10 and the risk grows with increasing maternal viremia (ie, HCV RNA > 105 copies/mL1). Risk for MTCT is heightened in women who are coinfected with HIV,3,11 with one systematic review showing a 10.8% vertical transmission risk among coinfected women, versus 5.8% among those with HCV infection alone.2 Transmission risk is increased in mothers with a history of IV drug use or a sexual partner infected with HCV.10 Perinatal procedures that expose the infant to HCV-infected maternal blood (eg, episiotomy, internal fetal monitoring) also elevate MTCT risk.3,7,1011
The recently approved regimen of sofosbuvir/ledipasvir [Harvoni®] has a pregnancy category of B, based on animal studies alone; its manufacturer recommends use of this regimen in pregnant patients only if its potential benefits exceed the potential risk to the fetus.8 Similarly, a pregnancy category of B (again, based only on animal studies) has been assigned to the combination of ombitasvir/paritaprevir/ritonavir with dasabuvir [Viekira Pak™], and its use during pregnancy is recommended “only if clearly needed”; additionally, its coadministration with ribavirin is absolutely contraindicated.9
In an effort to identify strategies to reduce vertical transmission of HCV, researchers for the US Preventive Services Task Force (USPSTF)6 performed a review of studies on the impact of mode of delivery, breastfeeding practices, and other factors on MTCT. No difference in HCV transmission was found in vaginal vs cesarean deliveries; however, in one good-quality study, a higher MTCT rate was found among cases involving prolonged duration of ruptured membranes (> 6 h before delivery).
Continue for association between breastfeeding and HCV >>
The USPSTF researchers found no association between breastfeeding and HCV transmission,6 although the CDC recommends against the practice in HCV-infected women whose nipples are cracked or bleeding.5 Of note, both breastfeeding and cesarean delivery are associated with increased transmission risk among HCV/HIV coinfected women.7 HCV genotype is reported to have little impact on MTCT.1,10
Until the development of an effective HCV vaccine and safe, effective HCV treatment for pregnant patients,1,3 strategies to interrupt MTCT represent our best hope to protect children against HCV infection.
REFERENCES
1. Yeung CY, Lee HC, Chan WT, et al. Vertical transmission of hepatitis C virus: current knowledge and perspectives. World J Hepatol. 2014;6(9):643-651.
2. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59(6):765-773.
3. Prasad MR, Honegger JR. Hepatitis C virus in pregnancy. Am J Perinatol. 2013;30(2):149-159.
4. Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period: are they opportunities for treatment? J Viral Hepat. 2011;18(4):229-236.
5. CDC. Hepatitis C FAQs for health professionals. www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed February 9, 2015.
6. Cottrell EB, Chou R, Wasson N, et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2013;158(2):109-113.
7. Tosone G, Maraolo AE, Mascolo S, et al. Vertical hepatitis C virus transmission: main questions and answers. World J Hepatol. 2014;6(8):538-548.
8. Harvoni®: highlights of prescribing information. www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed February 15, 2015.
9. Viekira Pak™: highlights of prescribing information. www.rxabbvie.com/pdf/viekirapak_pi.pdf. Accessed February 15, 2015.
10. Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. J Med Virol. 2009;81(5):8836-843.
11. Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192:1880-1889.
Hepatitis C virus (HCV) infection is reported in 0.05% to 0.36% of children in developed nations.1 Since improved screening of donor blood and blood products began in the 1990s, vertical transmission has become the primary cause of HCV infection in children.1-5 As many as 4,000 new cases of pediatric HCV infection may develop each year in the United States.6
At present, no clear interventions exist to prevent mother-to-child transmission (MTCT) of HCV.4,7 No HCV vaccine is yet available, and most current antiviral therapies are not considered safe for pregnant patients: ribavirin and interferon α, for example, are in pregnancy categories X and C, respectively.3,7 (See “Safer HCV Treatment Options in Pregnancy?”8,9) Some might argue that HCV infection is reported in only 1% to 2% of pregnant women in industrialized countries7 and that the rate of MTCT is low at 2% to 10%.3-5 Nevertheless, researchers maintain that HCV during pregnancy is a “neglected condition” and call for substantial improvements in public health response to affected patients.3,4 Awareness of risk factors for MTCT is essential.
Vertical transmission is believed to be limited to women with detectable viral load,3,4,10 and the risk grows with increasing maternal viremia (ie, HCV RNA > 105 copies/mL1). Risk for MTCT is heightened in women who are coinfected with HIV,3,11 with one systematic review showing a 10.8% vertical transmission risk among coinfected women, versus 5.8% among those with HCV infection alone.2 Transmission risk is increased in mothers with a history of IV drug use or a sexual partner infected with HCV.10 Perinatal procedures that expose the infant to HCV-infected maternal blood (eg, episiotomy, internal fetal monitoring) also elevate MTCT risk.3,7,1011
The recently approved regimen of sofosbuvir/ledipasvir [Harvoni®] has a pregnancy category of B, based on animal studies alone; its manufacturer recommends use of this regimen in pregnant patients only if its potential benefits exceed the potential risk to the fetus.8 Similarly, a pregnancy category of B (again, based only on animal studies) has been assigned to the combination of ombitasvir/paritaprevir/ritonavir with dasabuvir [Viekira Pak™], and its use during pregnancy is recommended “only if clearly needed”; additionally, its coadministration with ribavirin is absolutely contraindicated.9
In an effort to identify strategies to reduce vertical transmission of HCV, researchers for the US Preventive Services Task Force (USPSTF)6 performed a review of studies on the impact of mode of delivery, breastfeeding practices, and other factors on MTCT. No difference in HCV transmission was found in vaginal vs cesarean deliveries; however, in one good-quality study, a higher MTCT rate was found among cases involving prolonged duration of ruptured membranes (> 6 h before delivery).
Continue for association between breastfeeding and HCV >>
The USPSTF researchers found no association between breastfeeding and HCV transmission,6 although the CDC recommends against the practice in HCV-infected women whose nipples are cracked or bleeding.5 Of note, both breastfeeding and cesarean delivery are associated with increased transmission risk among HCV/HIV coinfected women.7 HCV genotype is reported to have little impact on MTCT.1,10
Until the development of an effective HCV vaccine and safe, effective HCV treatment for pregnant patients,1,3 strategies to interrupt MTCT represent our best hope to protect children against HCV infection.
REFERENCES
1. Yeung CY, Lee HC, Chan WT, et al. Vertical transmission of hepatitis C virus: current knowledge and perspectives. World J Hepatol. 2014;6(9):643-651.
2. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59(6):765-773.
3. Prasad MR, Honegger JR. Hepatitis C virus in pregnancy. Am J Perinatol. 2013;30(2):149-159.
4. Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period: are they opportunities for treatment? J Viral Hepat. 2011;18(4):229-236.
5. CDC. Hepatitis C FAQs for health professionals. www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed February 9, 2015.
6. Cottrell EB, Chou R, Wasson N, et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2013;158(2):109-113.
7. Tosone G, Maraolo AE, Mascolo S, et al. Vertical hepatitis C virus transmission: main questions and answers. World J Hepatol. 2014;6(8):538-548.
8. Harvoni®: highlights of prescribing information. www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed February 15, 2015.
9. Viekira Pak™: highlights of prescribing information. www.rxabbvie.com/pdf/viekirapak_pi.pdf. Accessed February 15, 2015.
10. Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. J Med Virol. 2009;81(5):8836-843.
11. Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192:1880-1889.